Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Tarsus Pharmaceuticals Chief Commercial Officer Aziz Mottiwala reported equity awards consisting of stock options and restricted stock units. He was granted stock options for 30,724 shares at an exercise price of $0.00, and 19,306 restricted stock units, each representing one share of common stock upon vesting.
Twenty‑five percent of the option shares vest on March 5, 2027, with the remaining options vesting monthly over three years, conditioned on continued service. The 19,306 RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, also subject to his continuous service.
Tarsus Pharmaceuticals, Inc. reported that Chief Operating Officer Neervannan Seshadri received new equity awards. On March 5, 2026, he was granted stock options for 27,310 shares at an exercise price of $0.00 per share, vesting 25% on March 5, 2027, with the remaining shares vesting monthly over three years, subject to continued service. He also received 17,161 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, contingent on his continued service.
Tarsus Pharmaceuticals reported that Chief Human Resources Officer Dianne C. Whitfield received new equity awards. On March 5, 2026, she was granted stock options for 27,310 shares at an exercise price of $0.00 and 17,161 Restricted Stock Units (RSUs).
Twenty-five percent of the option shares vest on March 5, 2027, with the remainder vesting monthly over the following three years, subject to continued service. The RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, with each RSU representing one share of common stock upon vesting.
Tarsus Pharmaceuticals Chief Medical Officer Elizabeth Yeu reported receiving new equity awards. On March 5, 2026, she was granted stock options for 27,310 shares at an exercise price of $0.00 per share and 17,161 Restricted Stock Units.
According to the terms, 25% of the option shares vest on March 5, 2027, with the remaining option shares vesting in equal monthly installments over the following three years, subject to continuous service. The RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, also conditioned on her continued service.
Tarsus Pharmaceuticals reported that President, CEO and Board Chair Bobak R. Azamian received new equity awards. He was granted a stock option for 96,723 shares at an exercise price of $0.00 per share and 60,776 Restricted Stock Units, both recorded as awards rather than open-market purchases.
The option will vest 25% on March 5, 2027, with the remaining shares vesting in equal monthly installments over the next three years, subject to his continuous service. The RSUs will vest in four equal annual installments on March 15 of 2027, 2028, 2029 and 2030, also contingent on continued service.
Tarsus Pharmaceuticals, Inc. Chief Operating Officer Neervannan Seshadri sold 8,366 shares of common stock in an open-market transaction on March 4, 2026 at $76.67 per share. The sale was executed automatically under a Rule 10b5-1 trading plan adopted on November 13, 2025. After the sale, he directly held 70,817 shares. The filing also reports 475 shares held by his daughter, for which he disclaims beneficial ownership.
Tarsus Pharmaceuticals files its annual report describing rapid growth of XDEMVY, its first approved eye-care drug for Demodex blepharitis, and a broader lotilaner-based pipeline. XDEMVY generated $451.4 million in net product sales in 2025, with about 400,000 bottles delivered and more than $646 million in sales since launch.
The company is advancing TP-04 into a Phase 2 trial for ocular rosacea, with topline data expected in the first half of 2027, and TP-05 into a Phase 2 Lyme disease prophylaxis trial planned to start in the second quarter of 2026. Tarsus highlights extensive licensing from Elanco, significant reliance on XDEMVY, single‑source manufacturing, and ongoing capital needs as key business risks.
Tarsus Pharmaceuticals reported strong fourth quarter and full-year 2025 growth driven by its Demodex blepharitis eye drop XDEMVY. Full-year 2025 net product sales of XDEMVY reached $451.4 million, an increase of more than 150% year-over-year, with fourth quarter net product sales of $151.7 million.
The company delivered about 400,000 bottles to patients in 2025 and maintained gross margins of 93%. Despite heavy investment in commercial and R&D spend, the full-year net loss narrowed to $66.4 million from $115.6 million, with basic and diluted loss per share improving to $(1.59) from $(3.07).
Tarsus ended 2025 with a strong cash position of $417.3 million in cash, cash equivalents and marketable securities. Management highlighted peak sales potential for XDEMVY of more than $2 billion and ongoing Phase 2 development for TP-04 in ocular rosacea and TP-05 for Lyme disease prevention.
PYOTT DAVID E I reported acquisition or exercise transactions in this Form 4 filing.
Tarsus Pharmaceuticals director David E. I. Pyott received new equity awards. On February 18, 2026, he was granted 5,893 stock options with a right to buy Tarsus common stock and 3,729 restricted stock units (RSUs).
The option grant will vest in three equal annual installments on February 18 of 2027, 2028, and 2029, contingent on his continuous service. Each RSU represents one share of common stock and will vest in three equal annual installments on March 15 of 2027, 2028, and 2029, also subject to continued service.